Draft genome sequences of three clinical isolates of teicoplanin-resistant Staphylococcus epidermidis from patients without prior exposure to glycopeptide antibiotics
Language English Country Netherlands Media print-electronic
Document type Journal Article, Research Support, Non-U.S. Gov't
PubMed
30797086
DOI
10.1016/j.jgar.2019.02.005
PII: S2213-7165(19)30045-1
Knihovny.cz E-resources
- Keywords
- Staphylococcus epidermidis, Teicoplanin resistance, Whole-genome sequencing,
- MeSH
- Anti-Bacterial Agents pharmacology MeSH
- Drug Resistance, Bacterial * MeSH
- Genome, Bacterial * MeSH
- Humans MeSH
- Microbial Sensitivity Tests MeSH
- Multilocus Sequence Typing MeSH
- Whole Genome Sequencing MeSH
- Staphylococcal Infections microbiology MeSH
- Staphylococcus epidermidis classification drug effects MeSH
- Bacterial Typing Techniques MeSH
- Teicoplanin pharmacology MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Names of Substances
- Anti-Bacterial Agents MeSH
- Teicoplanin MeSH
OBJECTIVES: The aim of this study was to analyse the DNA sequences of three teicoplanin-resistant Staphylococcus epidermidis isolates collected from patients not previously treated with glycopeptide antibiotics. METHODS: The minimum inhibitory concentrations (MICs) of 12 antibiotics, including teicoplanin and vancomycin, were determined by the broth microdilution method. Genomic DNA was isolated, was sequenced by HiSeqX paired-end sequencing and was assembled into draft genome sequences using MyPro pipeline. RESULTS: Analysis of the draft genome sequences demonstrated that the teicoplanin-resistant S. epidermidis isolates belonged to multilocus sequence typing (MLST) sequence types ST5 and ST87 and encoded multiple antimicrobial resistance genes, including the methicillin resistance gene mecA. CONCLUSIONS: This report highlights the risk of dissemination of S. epidermidis strains resistant to a wide range of clinically important antibiotics.
References provided by Crossref.org
Teicoplanin-A New Use for an Old Drug in the COVID-19 Era?
